1.888.321.7828 sales@pepid.com

FDA approves bremelanotide  (Vyleesi, AMAG Pharmaceuticals) to treat acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women.

Bremelanotide is the first-in-class melanocortin 4 receptor agonist for HSDD, and joins Flibanserin as treatment for HSDD.  

Bremelanotide is self-administered with a disposable autoinjector that activates melanocortin receptors. Patients inject Vyleesi (bremelanotide) under the skin of the abdomen or thigh a minimum of 45 minutes before sexual activity.

Common side effects are nausea, headaches and flushing.

Read the Full FDA Press Release here.

[elfsight_social_share_buttons id=”3″]

Share This